Information  X 
Enter a valid email address

Emirate of Abu Dhabi (OUT7)


Wednesday 15 September, 2021

Emirate of Abu Dhabi

Publication of Final Terms

RNS Number : 8965L
Emirate of Abu Dhabi
15 September 2021

Emirate of Abu Dhabi

Publication of Pricing Supplements


The following pricing supplements (the Pricing Supplements) are available for viewing:


1.  Pricing Supplement in relation to the issue of U.S.$1,750,000,000 1.875 per cent. Notes due 2031 by the Emirate of Abu Dhabi (the Issuer) under the Issuer's Global Medium Term Note Programme (the Programme)


2.  Pricing Supplement in relation to the issue of U.S.$1,250,000,000 3.000 per cent. Notes due 2051 by the Issuer under the Programme


Please read the disclaimer below "Disclaimer - Intended Addressees" before attempting to access this service, as your right to do so is conditional upon complying with the requirements set out below.

To view the full document, please paste the following URL into the address bar of your browser.

For further information, please contact:

Department of Finance

P.O. Box 246, Abu Dhabi

United Arab Emirates


Telephone:  +971 2 810 1714

Fax:  +971 2 622 9990

Email:  [email protected]





The Pricing Supplements referred to above must be read in conjunction with the offering circular dated 28 May 2021 in respect of the Programme, as supplemented by the supplement dated 8 September 2021 (the Offering Circular).


Please note that the information contained in the Pricing Supplements and the Offering Circular may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Pricing Supplements and/or the Offering Circular) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Pricing Supplements and/or the Offering Circular is not addressed.  Prior to relying on the information contained in the Pricing Supplements and/or the Offering Circular you must ascertain from the Pricing Supplements and Offering Circular whether or not you are part of the intended addressees of the information contained therein.


The securities referred to in the Pricing Supplements have not been and will not be registered under the United States Securities Act of 1933, as amended (the Securities Act) or with any securities regulatory authority of any state or other jurisdiction of the United States,and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Prospective purchasers are hereby notified that sellers of the Notes may be relying on the exemption from the provisions of Section 5 of the Securities Act provided by Rule 144A.


The Pricing Supplements has been made available to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission and consequently none of the Issuer, its advisers nor any person who controls any of them nor any director, officer, employee nor agent of it or affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the Final Terms made available to you in electronic format and the hard copy version available to you on request from the Issuer.


Your right to access this service is conditional upon complying with the above requirement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t